Advanced Glycation End Products Market, By Type (Non-fluorescent AGEs and Fluorescent AGEs), By Application (Diabetic, Cancer, Bone Diseases, Neurodegenerative Diseases, Others), By End User (Hospitals, Specialty Clinics, Homecare Settings, Others), By Ge

Advanced Glycation End Products Market, By Type (Non-fluorescent AGEs and Fluorescent AGEs), By Application (Diabetic, Cancer, Bone Diseases, Neurodegenerative Diseases, Others), By End User (Hospitals, Specialty Clinics, Homecare Settings, Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Global advanced glycation end products market growth is driven by increasing prevalence of diabetes and hypertension coupled with rising geriatric population worldwide. AGEs are molecules formed internally in the body as a result of non-enzymatic reactions between reducing sugars or carbohydrates and proteins or lipids. Accumulation of AGEs in the body causes damage by increasing oxidative stress and inflammation which can increase the risk of various chronic diseases. Due to growing health awareness, more research studies focusing on developing innovative AGE inhibition therapies can boost demand for AGE measurement tools and drugs to manage age-related conditions effectively.

Market Dynamics:

Global advanced glycation end products market growth is driven by factors like rising cases of diabetes and other lifestyle-related disorders, increasing aging population susceptible to chronic diseases, growing healthcare expenditure in developing nations, and ongoing research efforts to develop more effective AGE inhibitors. However, high costs associated with AGE detection technologies and lack of awareness can hamper the market growth. Developing low-cost point-of-care AGE measurement devices, establishing collaboration with research institutes, and expanding to emerging regions can offer opportunities for market players.

Key Features of the Study:

This report provides in-depth analysis of the global advanced glycation end products market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global advanced glycation end products market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Keryx Biopharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Amrax Bio, and others
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global advanced glycation end products market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global advanced glycation end products market

Detailed Segmentation-

• By Type
• Non-fluorescent AGEs
• Fluorescent AGEs
• By Application
• Diabetic Complications
• Cancer
• Bone Diseases
• Neurodegenerative Diseases
• Others
• By End User
• Hospitals
• Specialty Clinics
• Homecare Settings
• Other
• By Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa
• Company Profiles:
• Alteon Inc.
• Plexxikon Inc.
• Phenomenome Discoveries Inc.
• Kowa Company Ltd.
• Novartis International AG
• OPKO Health, Inc.
• DiabetOmics, Inc.
• Amadori Scientific
• LabCorp
• Quest Diagnostics Incorporated
• AstraZeneca plc
• Bayer AG
• Bristol-Myers Squibb Company
• Pfizer Inc.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Eli Lilly and Company
• Sanofi S.A.